OncoMatch/Clinical Trials/NCT07046923
A Study of LY4175408 in Participants With Advanced Cancer
Is NCT07046923 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies LY4175408 for carcinoma, non-small-cell lung.
Treatment: LY4175408 — The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Endometrial Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Disease stage
Metastatic disease required
advanced or metastatic solid tumor cancers
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: all standard therapies for which the individual was deemed to be an appropriate candidate
Received all standard therapies for which the individual was deemed to be an appropriate candidate by the treating investigator; OR the individual is refusing the remaining most appropriate standard of care treatment; OR there is no standard therapy available for the disease
Cannot have received: PTK7 antibody-drug conjugate with a topoisomerase I inhibitor payload
Exception: prior therapy with a PTK7 ADC with a non-topoisomerase I inhibitor payload OR non-PTK7 ADC with any payload is permitted
Prior treatment with a protein tyrosine kinase 7 (PTK7) antibody-drug conjugate (ADC) with a topoisomerase I inhibitor as payload
Lab requirements
Cardiac function
Significant cardiovascular disease; QTcF > 470 ms
Significant cardiovascular disease. Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) > 470 milliseconds (ms)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Cancer Center · Stanford, California
- Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute · Orlando, Florida
- Florida Cancer Specialists - Sarasota · Sarasota, Florida
- The University of Chicago Medical Center (UCMC) · Chicago, Illinois
- Community Health Network · Indianapolis, Indiana
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify